(Q38063789)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

review article

1 reference

title

Reducing safety-related drug attrition: the use of in vitro pharmacological profiling (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

author name string

Joanne Bowes

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Jacques Hamon

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Wolfgang Jarolimek

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Arun Sridhar

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Gareth Waldron

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Steven Whitebread

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

language of work or name

1 reference

1 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

19 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

page(s)

909-922

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23197038%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd3845

19 February 2020

exact match

0 references

cites work

Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?

1 reference

Safety pharmacology--a progressive approach

31 March 2020

1 reference

A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel

31 March 2020

1 reference

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

31 March 2020

1 reference

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

31 March 2020

1 reference

Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment

31 March 2020

1 reference

Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development

31 March 2020

1 reference

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

31 March 2020

1 reference

Teratogenic effects of the endothelin receptor antagonist L-753,037 in the rat

31 March 2020

1 reference

Muscarinic receptor subtypes

31 March 2020

1 reference

Drugs with anticholinergic properties: a current perspective on use and safety.

31 March 2020

1 reference

Screening technologies for ion channel drug discovery

31 March 2020

1 reference

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

31 March 2020

1 reference

Cardiotoxicity associated with targeting kinase pathways in cancer

31 March 2020

1 reference

Transformation of in vitro tools for kinase profiling: keeping an eye over the off-target liabilities

31 March 2020

1 reference

GPCR Molecular Pharmacology and Drug Targeting

31 March 2020

1 reference

Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.

31 March 2020

1 reference

Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks.

31 March 2020

1 reference

In vitro safety pharmacology profiling: what else beyond hERG?

31 March 2020

1 reference

Safety and secondary pharmacology: successes, threats, challenges and opportunities

31 March 2020

1 reference

Translation of flecainide- and mexiletine-induced cardiac sodium channel inhibition and ventricular conduction slowing from nonclinical models to clinical

31 March 2020

1 reference

Antiarrhythmic drugs and torsade de pointes

31 March 2020

1 reference

The influence of drug-like concepts on decision-making in medicinal chemistry

31 March 2020

1 reference

Modeling promiscuity based on in vitro safety pharmacology profiling data

31 March 2020

1 reference

Physiochemical drug properties associated with in vivo toxicological outcomes

31 March 2020

1 reference

Can we discover pharmacological promiscuity early in the drug discovery process?

31 March 2020

1 reference

Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds

31 March 2020

1 reference

Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitors

31 March 2020

1 reference

An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation

31 March 2020

1 reference

On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex

31 March 2020

1 reference

The predictive validity of the rat self-administration model for abuse liability.

31 March 2020

1 reference

How many drug targets are there?

31 March 2020

1 reference

In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.

31 March 2020

1 reference

In silico tools for sharing data and knowledge on toxicity and metabolism: derek for windows, meteor, and vitic

31 March 2020

1 reference

In silico pharmacology for drug discovery: applications to targets and beyond

31 March 2020

1 reference

Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure

31 March 2020

1 reference

Computational methods for early predictive safety assessment from biological and chemical data

31 March 2020

1 reference

Large-scale prediction and testing of drug activity on side-effect targets

31 March 2020

1 reference

Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics

31 March 2020

1 reference

Translational toxicology and the work of the predictive safety testing consortium

31 March 2020

1 reference

Activity profiles of 309 ToxCast™ chemicals evaluated across 292 biochemical targets

31 March 2020

1 reference

BindingDB and ChEMBL: online compound databases for drug discovery

31 March 2020

1 reference

Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk

31 March 2020

1 reference

Minimum information about a bioactive entity (MIABE).

31 March 2020

1 reference

The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation

31 March 2020

1 reference

Genome-wide association study of PR interval

31 March 2020

1 reference

Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation.

31 March 2020

1 reference

Adenosine and its receptors: multiple modulatory functions and potential therapeutic targets for neurologic disease

31 March 2020

1 reference

Alpha 1-adrenergic receptor regulation: basic science and clinical implications

31 March 2020

1 reference

Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough

31 March 2020

1 reference

What is the role of beta-adrenergic signaling in heart failure?

31 March 2020

1 reference

Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease

31 March 2020

1 reference

The future of endocannabinoid-oriented clinical research after CB1 antagonists.

31 March 2020

1 reference

Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease

31 March 2020

1 reference

Cholecystokinin and gastrin receptors

31 March 2020

1 reference

Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions

31 March 2020

1 reference

Dopamine receptors--physiological understanding to therapeutic intervention potential

31 March 2020

1 reference

Endothelin receptor antagonists: status and learning 20 years on.

31 March 2020

1 reference

Emerging safety issues regarding long-term usage of H(1)receptor antagonists

31 March 2020

1 reference

31 March 2020

1 reference

Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans

31 March 2020

1 reference

Effects of central muscarinic-1 receptor stimulation on blood pressure regulation

31 March 2020

1 reference

A Mechanism for Rapacuronium-induced Bronchospasm

31 March 2020

1 reference

5-HT1A receptor, an old target for new therapeutic agents

31 March 2020

1 reference

ICV injection of the serotonin 5-HT1B agonist CP-93,129 increases the secretion of ACTH, prolactin, and renin and increases blood pressure by nonserotonergic mechanisms

31 March 2020

1 reference

Drug-induced serotonin syndrome: a review.

31 March 2020

1 reference

Drugs and valvular heart disease

31 March 2020

1 reference

Vasopressin: mechanisms of action on the vasculature in health and in septic shock

31 March 2020

1 reference

Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity.

31 March 2020

1 reference

Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism

31 March 2020

1 reference

Effectiveness of benzodiazepines: do they work or not?

31 March 2020

1 reference

A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome

31 March 2020

1 reference

Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?

31 March 2020

1 reference

Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research

31 March 2020

1 reference

5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile

31 March 2020

1 reference

Cardiac sodium channels and inherited electrophysiologic disorders: a pharmacogenetic overview

31 March 2020

1 reference

Experimental and clinical toxicology of anticholinesterase agents.

31 March 2020

1 reference

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities

31 March 2020

1 reference

Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation

31 March 2020

1 reference

Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor

31 March 2020

1 reference

Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?

31 March 2020

1 reference

PDE4 inhibitors: current status

31 March 2020

1 reference

Defective expression of p56lck in an infant with severe combined immunodeficiency

31 March 2020

1 reference

The dopamine transporter: role in neurotoxicity and human disease

31 March 2020

1 reference

Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans.

31 March 2020

1 reference

Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects

31 March 2020

1 reference

Biological Actions of Androgens

31 March 2020

1 reference

31 March 2020

1 reference

Drug insight: selective agonists and antagonists of the glucocorticoid receptor

31 March 2020

1 reference

The determination and interpretation of the therapeutic index in drug development

31 March 2020

1 reference

Cardiac histamine receptors: their pharmacological consequences and signal transduction pathways

31 March 2020

1 reference

12 December 2020

Phosphodiesterase III inhibitors for heart failure

1 reference

12 December 2020

A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism

1 reference

12 December 2020

Predicting ADME properties and side effects: the BioPrint approach.

1 reference

12 December 2020

Drug withdrawals and the lessons within.

1 reference

12 December 2020

Anti-inflammatory and side effects of cyclooxygenase inhibitors.

1 reference

12 December 2020

1 reference

12 December 2020